BioMarin Pharmaceutical Inc.
BMRN Details
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is a global biotechnology business that develops and commercializes innovative medications for rare and potentially fatal genetic diseases. Its pharmaceutical portfolio includes seven commercially available drugs (Vimizim, Naglazyme, Kuvan, Palynziq, Brineura, Voxzogo, and Aldurazyme) and other clinical and pre-clinical prospects.
Latest News:
- Contract with Entos: On November 15, 2021, BMRN announced a deal in which Entos, a clinical-stage biotechnology firm, under which Entos would apply its Fusogenix nucleic acid delivery technology to potential gene therapy candidates in the BMRN pipeline. Entos will also develop specifically formulated product candidates for BMRN under the terms of the contract.
- Appointing New R&D and Technical Heads: On October 04, 2021, BMRN announced the appointment of two industry veterans, Mr. Harold S. Bernstein as Senior Vice President, Chief Medical Officer, and Head of Clinical Development, and Mr. Ganesh Vedantham as Senior Vice President, Technical Development, to fill two critical strategic roles.
Q3FY21 Results:
- Fall in Revenues: Due to reduced Kuvan, Aldurazyme, Vimizim, and Naglazyme product revenues, BMRN reported a 14.27% reduction in revenues to USD 408.74 million in Q3FY21 (ended September 30, 2021) compared to USD 476.78 million in Q3FY20.
- Recorded Net Losses: The company witnessed a net loss of USD 36.49 million in Q3FY21 vs. a net profit of USD 784. 80 million in Q3FY20.
- Decent Balance Sheet: BMRN ended the quarter with a cash balance of USD 1.08 billion (including short-term investments) and total debt of USD 1.08 billion.
Key Risks:
- Pricing Control: The government primarily controls pricing in the pharmaceutical business. Therefore, any limitation on the amount BMRN may charge for its products can harm its revenue and results of operations.
- Regulatory Scrutiny: Prior approvals may be suspended or withdrawn from BMRN if its products fail to meet regulatory criteria, which might negatively impact its financial position.
Outlook:
- Revenues & Net Income Estimates: BMRN indicated in its Q3FY21 earnings release that its FY21 revenues would range between USD 1.82 and 1.88 billion, with a GAAP net loss of USD 45 to 85 million. Non-GAAP net income is expected to range between USD 215 and 255 million.
- Operating Expenses: Its R&D and selling, general, and administrative (SG&A) costs are expected to range from USD 635 to 675 million and USD 735 to 775 million, respectively.
Valuation Methodology: EV/Sales Multiple Based Relative Valuation
(Analysis by Kalkine Group)
* % Premium/(Discount) is based on our assessment of the company's NTM trading multiple after considering its key growth drivers, economic moat, stock's historical trading multiples versus peer average/median, and investment risks.
BMRN Daily Technical Chart (Source: REFINITIV)
Stock Recommendation:
BMRN's stock price has surged 12.07% in the past month and is currently trading close to the mid-band of the 52-week range of USD 71.59 to USD 92.57. The stock is currently trading above its 50 and 200 DMA levels, and its RSI Index is 61.45. We have valued the stock using the EV/Sales-based relative valuation methodology and arrived at a target price of USD 78.62.
Considering the decline in financials, current valuation, and other technical indicators, we believe the decent business fundamentals are sufficiently reflected at current trading levels. Hence, we recommend a "Sell" rating on the stock at the current price of USD 83.12, up 2.95% as of November 18, 2021, at 2:40 PM ET.
* The reference data in this report has been partly sourced from REFINITIV.
* All forecasted figures and industry information have been taken from REFINITIV.
Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.